Redcon1's 11 Bravo is a natural anabolic supplement that promotes lean muscle tissue.
Mediator is a patended brand ingredient/compound which has demonstrated in a university study to provide double muscle mass gain, increased strength, and double the fat loss in individuals who are engaged in weight training. More recently it was discovered that orally ingested Phosphatidic Acid (PA) when accompanied with resistance training and protein intake, significantly activates the Mammalian Target of Rapamycin (mTOR) signalling pathway.
What mTOR does is regulate protein synthesis allowing ingested proteins to be converted into new muscle.
Yes both men and women can take Redcon1 11 Bravo.
Redcon1 11 Bravo contains 750mg of Mediator.
Take one serving (2 capsules) once per day in the morning with a protein rich meal or protein shake. For best results use 11 Bravo in conjunction with a resistance based training regiment and a protein rich diet.
Serving Size: 2 Capsules
Servings Per Container: 30
Mediator PA (Phosphatidic Acid) 750mg
Other Ingredients: Gelatin, Dicalcium phosphate, Microcrystalline cellulose, Magnesium stearate, Silica.
Escalante G, Alencar M, Haddock B, Harvey P. The effects of phosphatidic acid supplementation on strength, body composition, muscular endurance, power, agility, and vertical jump in resistance trained men. J Int Soc Sports Nutr. 2016;13:24. Published 2016 Jun 2. doi:10.1186/s12970-016-0135-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891923/
Andre TL, Gann JJ, McKinley-Barnard SK, Song JJ, Willoughby DS. Eight Weeks of Phosphatidic Acid Supplementation in Conjunction with Resistance Training Does Not Differentially Affect Body Composition and Muscle Strength in Resistance-Trained Men. J Sports Sci Med. 2016;15(3):532–539. Published 2016 Aug 5.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974867/
Bond P. Phosphatidic acid: biosynthesis, pharmacokinetics, mechanisms of action and effect on strength and body composition in resistance-trained individuals. Nutr Metab (Lond). 2017;14:12. Published 2017 Feb 6. doi:10.1186/s12986-017-0166-6
